Innovative Therapy Platform HistoSonics offers a cutting-edge non-invasive sonic beam therapy platform utilizing histotripsy technology, presenting unique opportunities to expand into hospitals and cancer treatment centers seeking advanced, tissue-specific treatment options.

Strong Financial Backing The company has secured substantial funding, including a recent $2.25 billion investment, demonstrating investor confidence and enabling aggressive expansion, product development, and market penetration activities.

Expanding Market Presence With upcoming participation in industry events like DeviceTalks Minnesota and partnerships with organizations such as Proximie, HistoSonics is actively increasing its visibility among healthcare providers and decision-makers, ideal for identifying new sales leads.

Growing Footprint and Reach Headquartered in Minneapolis with other regional offices and recent recognition like the NVCA Startup Innovator Award, the company's expanding geographic footprint offers ample opportunities to target regional hospitals and specialty clinics.

Leadership and Industry Validation Led by experienced industry experts including CEO Mike Blue, with a focus on oncology and groundbreaking treatments, HistoSonics is positioning itself as a leader in minimally invasive therapies, opening avenues for strategic partnerships and enterprise account sales.